The unit METAB-OMICS – “Multi-omics and the pathophysiology of metabolic diseases”Led by Amélie Bonnefond, brings together researchers, clinicians, teachers, engineers and technicians around the integrated study of metabolic diseases such as diabetes, obesity and their complications.

The unit is placed under the supervision of the CNRS, Inserm, the University of Lille, the Pasteur Institute of Lille and University Hospital of Lille.

METAB-OMICS is structured in two certified research teams :

• Team 1 – “(Epi)genomics of metabolic diseases”Led by Amélie Bonnefond (DR1 Inserm)This research team explores the genetic and epigenetic bases of metabolic diseases using next-generation genomic and multi-omics approaches. They are particularly interested in common multifactorial forms of type 2 diabetes and obesity (known as polygenic), as well as rarer, monogenic forms in which a single mutation can be sufficient to cause the disease. The goal is to identify new genes and signaling pathways, including epigenetic pathways, involved in these pathologies, in order to improve our understanding of them and contribute to the identification of new therapeutic targets, better patient stratification, and the development of precision medicine approaches.
• Team 2 – “Metabolome, Microbiome and Metabolic Diseases”Led by Marc-Emmanuel Dumas (DR2 CNRS)This team studies the interactions between the metabolome, the microbiome, and the pathophysiology of metabolic diseases. Their research focuses particularly on the role of the metabolome in cardiometabolic diseases to better understand the integrated regulatory mechanisms of metabolism, combining approaches from genomics, microbiomics, and systems biology. The team is especially interested in the influence of the microbiome and its metabolic products on metabolic and cardiorespiratory diseases. They use metabolomics to identify new biomarkers and decipher the mechanisms involved in these pathologies, as well as in chronic inflammatory processes, including neuroinflammation.

The scientific activities of both teams are based on two major technological platformsopen to the scientific community:

• LIGAN, associated with team 1, specializing in the multi-omics technologies based primarily on next-generation sequencing (NGS) and large-scale genomic analysis

Learn More

• IMPACT-PM, associated with team 2, dedicated to the high-resolution mass spectrometry-based metabolomics, with particular expertise in the study of microbiota-derived metabolites.

Learn More

Thanks to these infrastructures and its multidisciplinary expertise, the METAB-OMICS unit develops integrative approaches aimed at better understanding the mechanisms of metabolic diseases and contributing to the development of precision medicine.